Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Cited by (249)

Items 201–249 of 249

1. Aging, immune senescence, and immunotherapy: a comprehensive review
   Elias, Rawad, Hartshorn, Kevan, Rahma, Osama, Lin, Nina, Snyder-Cappione, Jennifer E. · 2018 · Seminars in Oncology
2. Product review: Avelumab, an anti-PD-L1 antibody
   Collins, Julie M., Gulley, James L. · 2019 · Human Vaccines & Immunotherapeutics
3. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
   Shire, Norah J., Klein, Alyssa B., Golozar, Asieh, Collins, Jenna M., Fraeman, Kathy H., Nordstrom, Beth L., McEwen, Robert, Hembrough, Todd, Rizvi, Naiyer A. · 2020 · PLOS ONE
4. Neurological sequelae of cancer immunotherapies and targeted therapies
   Wick, Wolfgang, Hertenstein, Anne, Platten, Michael · 2016 · The Lancet Oncology
5. Irradiation and immunotherapy: From concept to the clinic
   Salama, April K. S., Postow, Michael A., Salama, Joseph K. · 2016 · Cancer
6. Characterization of TAP Ambr 250 disposable bioreactors, as a reliable scale‐down model for biologics process development
   Xu, Ping, Clark, Colleen, Ryder, Todd, Sparks, Colleen, Zhou, Jiping, Wang, Michelle, Russell, Reb, Scott, Charo · 2017 · Biotechnology Progress
7. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
   Passiglia, Francesco, Cappuzzo, Federico, Alabiso, Oscar, Bettini, Anna Cecilia, Bidoli, Paolo, Chiari, Rita, Defferrari, Carlotta, Delmonte, Angelo, Finocchiaro, Giovanna, Francini, Guido et al. · 2019 · British Journal of Cancer
8. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
   Cousin, Sophie, Italiano, Antoine · 2016 · Clinical Cancer Research
9. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
   Horisberger, Alice, La Rosa, Stefano, Zurcher, Jean-Philippe, Zimmermann, Stefan, Spertini, Francois, Coukos, George, Obeid, Michel · 2018 · Journal for ImmunoTherapy of Cancer
10. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
    Piotrowska, Z., Costa, D.B., Oxnard, G.R., Huberman, M., Gainor, J.F., Lennes, I.T., Muzikansky, A., Shaw, A.T., Azzoli, C.G., Heist, R.S. et al. · 2018 · Annals of Oncology
11. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
    Okada, Norio, Iwama, Shintaro, Okuji, Takayuki, Kobayashi, Tomoko, Yasuda, Yoshinori, Wada, Eri, Onoue, Takeshi, Goto, Motomitsu, Sugiyama, Mariko, Tsunekawa, Taku et al. · 2020 · British Journal of Cancer
12. Immune Microenvironment Differences Between Squamous and Non-squamous Non–small-cell Lung Cancer and Their Influence on the Prognosis
    Meng, Xiangjiao, Gao, Yongsheng, Yang, Lian, Jing, Haiyan, Teng, Feifei, Huang, Zhaoqin, Xing, Ligang · 2019 · Clinical Lung Cancer
13. Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer
    Choi, Hyejin, Deng, Jiehui, Li, Shuai, Silk, Tarik, Dong, Lauren, Brea, Elliott J., Houghton, Sean, Redmond, David, Zhong, Hong, Boiarsky, Jonathan et al. · 2019 · Cell Reports
14. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
    Kanz, Bridgette A., Pollack, Megan H., Johnpulle, Romany, Puzanov, Igor, Horn, Leora, Morgans, Alicia, Sosman, Jeffrey A., Rapisuwon, Suthee, Conry, R. Martin, Eroglu, Zeynep et al. · 2016 · Journal for ImmunoTherapy of Cancer
15. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
    Derosa, Lisa, Routy, Bertrand, Kroemer, Guido, Zitvogel, Laurence · 2018 · OncoImmunology
16. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support
    Chae, Young Kwang, Pan, Alan P., Davis, Andrew A., Patel, Sandip P., Carneiro, Benedito A., Kurzrock, Razelle, Giles, Francis J. · 2017 · Molecular Cancer Therapeutics
17. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study
    Kim, Hyunho, Lee, Ji Eun, Hong, Sook Hee, Lee, Myung Ah., Kang, Jin Hyoung, Kim, In-Ho · 2019 · BMC Cancer
18. Trial watch: immune checkpoint blockers for cancer therapy
    Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C. et al. · 2017 · OncoImmunology
19. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab
    Baxi, Vipul, Lee, George, Duan, Chunzhe, Pandya, Dimple, Cohen, Daniel N., Edwards, Robin, Chang, Han, Li, Jun, Elliott, Hunter, Pokkalla, Harsha et al. · 2022 · Modern Pathology
20. Dendritic cells as cancer therapeutics
    Bryant, Christian E., Sutherland, Sarah, Kong, Benjamin, Papadimitrious, Michael S., Fromm, Phillip D., Hart, Derek N.J. · 2019 · Seminars in Cell & Developmental Biology
21. Immune checkpoint inhibitors in older adults
    Elias, Rawad, Morales, Joshua, Rehman, Yasser, Khurshid, Humera · 2016 · Current Oncology Reports
22. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
    Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schöb, O., Mannhart, M., Oweira, H. · 2017 · Clinical Oncology
23. LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
    Bonanno, Laura, De Paoli, Angela, Zulato, Elisabetta, Esposito, Giovanni, Calabrese, Fiorella, Favaretto, Adolfo, Santo, Antonio, Conte, Alessandro Del, Chilosi, Marco, Oniga, Francesco et al. · 2017 · Clinical Cancer Research
24. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
    Jo, Wonyoung, Won, Taejoon, Daoud, Abdel, Čiháková, Daniela · 2024 · Frontiers in Immunology
25. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer
    Wu, Jia, Li, Xuejie, Teng, Xiaodong, Rubin, Daniel L., Napel, Sandy, Daniel, Bruce L., Li, Ruijiang · 2018 · Breast Cancer Research
26. Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
    Noordam, Lisanne, Kaijen, Margaretha E.H., Bezemer, Koen, Cornelissen, Robin, Maat, Lex A.P.W.M., Hoogsteden, Henk C., Aerts, Joachim G.J.V., Hendriks, Rudi W., Hegmans, Joost P.J.J, Vroman, Heleen · 2018 · OncoImmunology
27. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors
    Li, Yangyang, Zhang, Yu, Cao, Guoshuai, Zheng, Xiaodong, Sun, Cheng, Wei, Haiming, Tian, Zhigang, Xiao, Weihua, Sun, Rui, Sun, Haoyu · 2021 · Journal of Hematology & Oncology
28. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
    2018 · In Vivo
29. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection
    Pertejo-Fernandez, Ana, Ricciuti, Biagio, Hammond, Sarah P., Marty, Francisco M., Recondo, Gonzalo, Rangachari, Deepa, Costa, Daniel B., Awad, Mark M. · 2020 · Lung Cancer
30. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
    Abdel-Rahman, Omar, Fouad, Mona · 2016 · Immunotherapy
31. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma
    Gong, Zhihua, Jia, Qingzhu, Chen, Junying, Diao, Xinwei, Gao, Jianbao, Wang, Xinxin, Zhu, Bo · 2019 · Journal of Thoracic Oncology
32. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer
    Funaki, Soichiro, Shintani, Yasushi, Kawamura, Tomohiro, Kanzaki, Ryu, Minami, Masato, Okumura, Meinoshin · 2017 · Oncology Reports
33. Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
    Carbone, D.P., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Felip, E., Cheng, Y., Juan-Vidal, O. et al. · 2025 · ESMO Open
34. Photodynamic therapy of lung cancer, where are we?
    Crous, Anine, Abrahamse, Heidi · 2022 · Frontiers in Pharmacology
35. Total metabolic tumor volume on ¹⁸ F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
    Tricarico, Pierre, Chardin, David, Martin, Nicolas, Contu, Sara, Hugonnet, Florent, Otto, Josiane, Humbert, Olivier · 2024 · Journal for ImmunoTherapy of Cancer
36. Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
    Patkar, Sushant, Chen, Alex, Basnet, Alina, Bixby, Amber, Rajendran, Rahul, Chernet, Rachel, Faso, Susan, Kumar, Prashanth Ashok, Desai, Devashish, El-Zammar, Ola et al. · 2024 · npj Precision Oncology
37. The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma
    Gudowska-Sawczuk, Monika, Kudelski, Jacek, Mroczko, Barbara · 2020 · International Journal of Molecular Sciences
38. Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors
    Castello, Angelo, Rossi, Sabrina, Toschi, Luca, Lopci, Egesta · 2021 · Journal of Clinical Medicine
39. Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline.
    Zhou, Xin, Iwama, Shintaro, Kobayashi, Tomoko, Ando, Masahiko, Arima, Hiroshi · 2023 · The Journal of Clinical Endocrinology & Metabolism
40. Immunotherapy in Glioblastoma: A Clinical Perspective
    Desbaillets, Nicolas, Hottinger, Andreas Felix · 2021 · Cancers
41. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
    Hoefsmit, Esmée P., Rozeman, Elisa A., Haanen, John B.A.G., Blank, Christian U. · 2019 · ESMO Open
42. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Zhao, Dan, Li, Haiqing, Mambetsariev, Isa, Mirzapoiazova, Tamara, Chen, Chen, Fricke, Jeremy, Kulkarni, Prakash, Villaflor, Victoria, Arvanitis, Leonidas, Hamilton, Stanley et al. · 2022 · Cancers
43. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
    Koyama, Junji, Horiike, Atsushi, Yoshizawa, Takahiro, Dotsu, Yosuke, Ariyasu, Ryo, Saiki, Masafumi, Sonoda, Tomoaki, Uchibori, Ken, Nishikawa, Shingo, Kitazono, Satoru et al. · 2019 · Journal of Thoracic Disease
44. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
    Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A. et al. · 2021 · Annals of Oncology
45. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
    Katayama, Yuki, Yamada, Tadaaki, Tanimura, Keiko, Yoshimura, Akihiro, Takeda, Takayuki, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi · 2019 · Thoracic Cancer
46. Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
    Mendes, Cindy, Serpa, Jacinta · 2019 · Antioxidants
47. The Role of PET Molecular Imaging in Immune Checkpoint Inhibitor Therapy in Lung Cancer: Precision Medicine and Visual Monitoring
    Yao, Yuan, Zhou, Xin, Zhang, Annan, Ma, Xiaopan, Zhu, Hua, Yang, Zhi, Li, Nan · 2022 · European Journal of Radiology
48. Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
    Wang, Yungang, Deng, Shouyan, Xu, Jie · 2020 · Cancer Biology and Medicine
49. SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab
    Kolkıran, Nagihan, Erdoğan, Atike Pınar, Şahbazlar, Mustafa, Taş, Semra, Gököz Doğu, Gamze, Canaslan, Kübra, Ünek, İlkay Tuğba, Demirkıran, Özge, Demir, Bilgin, Teküstün, Güler Nur et al. · 2025 · Current Oncology